Biomarkers for Alzheimer's disease: Showing the way or leading us astray?

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a 'presymptomatic' stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine 'go- no go' decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease.

Original languageEnglish (US)
JournalJournal of Alzheimer's Disease
Volume33
Issue numberSUPPL. 1
DOIs
StatePublished - 2013

Fingerprint

Alzheimer Disease
Biomarkers
Asymptomatic Diseases
Patient Selection
Clinical Trials
Pharmaceutical Preparations
Therapeutics

Keywords

  • Alzheimer's disease
  • biomarkers
  • clinical trials

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Biomarkers for Alzheimer's disease : Showing the way or leading us astray? / Quinn, Joseph.

In: Journal of Alzheimer's Disease, Vol. 33, No. SUPPL. 1, 2013.

Research output: Contribution to journalArticle

@article{ceaa6ad5298d4099af56693d0b82f43b,
title = "Biomarkers for Alzheimer's disease: Showing the way or leading us astray?",
abstract = "The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a 'presymptomatic' stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine 'go- no go' decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease.",
keywords = "Alzheimer's disease, biomarkers, clinical trials",
author = "Joseph Quinn",
year = "2013",
doi = "10.3233/JAD-2012-129022",
language = "English (US)",
volume = "33",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Biomarkers for Alzheimer's disease

T2 - Showing the way or leading us astray?

AU - Quinn, Joseph

PY - 2013

Y1 - 2013

N2 - The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a 'presymptomatic' stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine 'go- no go' decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease.

AB - The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a 'presymptomatic' stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine 'go- no go' decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease.

KW - Alzheimer's disease

KW - biomarkers

KW - clinical trials

UR - http://www.scopus.com/inward/record.url?scp=84872571276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872571276&partnerID=8YFLogxK

U2 - 10.3233/JAD-2012-129022

DO - 10.3233/JAD-2012-129022

M3 - Article

C2 - 22766735

AN - SCOPUS:84872571276

VL - 33

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - SUPPL. 1

ER -